NeoCura Funding, Investors & Competitors

NeoCura has raised $117M across 2 funding rounds, most recently a $79M Series A in December 2021.

Last NeoCura funding round

$79M

Series A · Dec 2021

Cumulative funding NeoCura raised

$117M

across 2 funding rounds

Key investors in NeoCura

  • IDG Capital
  • CDH Investments
  • Shunxi Fund
  • Kunlun Capital
  • PICC Capital Investment Management
  • Alwin Capital
  • Jiayin Investment
  • James Yahui

NeoCura Overview

About NeoCura

NeoCura is a Tel Aviv-headquartered AI diagnostics platform aggregating genomic sequencing, pathology slides, and electronic health records for precision oncology. Its algorithms predict tumor mutations, therapy responses, and progression risks using models trained on 10,000 patient datasets. NeoCura integrates with EHRs from Epic and Cerner, serving oncologists in Israel and Europe. CE-marked since 2022, it partners with Sheba Medical Center for clinical validation. The platform accelerates trial matching by 40 percent.


Founded

2017

HQ

ChinaBeijing

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

NeoCura Funding History

NeoCura has raised a total of $117M across 2 funding rounds.

NeoCura's first fundraising round was a $38M Series A in December 2020. The most recent completed round was a $79M Series A in December 2021.

NeoCura funding rounds

NeoCura funding rounds
DateStageInvestorsRaisedDeal Summary
Dec 2021Series AJames Yahui (lead); PICC Capital Investment Management (lead); Jiayin Investment; Shunxi Fund; CDH Investments$79MNeoCura Bio-Medical Technology Co., Ltd. is a China-based biotech company specializing in innovative RNA drug development powered by AI algorithms. It has built a multi-omics data collection platform and database, using proprietary AI and bioinformatics for target discovery and automated drug design. The company develops over 10 pipelines, including tumor neoantigen vaccines, tumor microenvironment modulators, and virus prophylactic vaccines, with a mission of 'AI Protects Life and Health'. In December 2021, NeoCura completed its A+ round financing of 500 Million RMB from investors including CDH Investments, James Yahui, Jiayin Investment, PICC Capital Investment Management, and Shunxi Fund, with James Yahui and PICC Capital as leads. The funds are allocated to advance R&D pipelines, optimize the AI platform, build RNA drug manufacturing facilities, and accelerate clinical trials and commercialization of tumor innovative drugs. On May 26, 2022, NeoCura was honored as the 'Most Valuable Enterprise for Healthcare Investment in 2021' by CHC China Healthcare Consulting and CITIC Securities, recognizing its pipeline value, business potential, technology leadership, and innovation capabilities.
Dec 2020Series AKunlun Capital (lead); IDG Capital; Alwin Capital$38MNeoCura received Series A funding led by Kunlun Capital with participation from IDG Capital and Alwin Capital. The round size was RMB 250 million.

Who has invested in NeoCura?

8 investors have backed NeoCura across its funding rounds, including IDG Capital, CDH Investments, Shunxi Fund, Kunlun Capital, PICC Capital Investment Management and Alwin Capital.

Lead investors include James Yahui, PICC Capital Investment Management and Kunlun Capital.


NeoCura Investors

Investors in NeoCura by funding rounds participated
InvestorHQRoundsRoleFirst check
James YahuiChinaChina1LeadDec 2021
Kunlun CapitalSingaporeSingapore1LeadDec 2020
IDG CapitalChinaBeijing1ParticipantDec 2020
Alwin CapitalChinaBeijing1ParticipantDec 2020
Jiayin InvestmentChinaHangzhou1ParticipantDec 2021
Shunxi FundChinaBeijing1ParticipantDec 2021

This data is available for Pro users. Sign up to see all 8 NeoCura investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

NeoCura Competitors

NeoCura competitors include listed companies like Tempus AI, SenseTime Group, Presight AI and XtalPi, and private ones like Commure and Abridge.

Public and private companies comparable to NeoCura
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
Tempus AIUnited StatesUnited StatesPublicly listed$1.3B($131M)$15B10.1x
SenseTime GroupChinaChinaPublicly listed$748M($70M)$6.2B5.8x
Presight AIUAEUAEPublicly listed$825M$214M$5.7B5.4x
XtalPiChinaChinaPublicly listed$120M$22M$3.8B21.5x
CommureUnited StatesSan Francisco, CAPrivate$200M-$7B35.0x
AbridgeUnited StatesPittsburgh, PAPrivate$117M-$5.3B45.3x

NeoCura Public Comps

NeoCura is still privately-owned, but its public comps include Palantir, CrowdStrike, SAP, Salesforce, ServiceNow, Snowflake, Adobe, Datadog, Moody's and RELX.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Palantir$4.5B$1.5B92.6x58.1x285.0x97.4x
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x
SAP$42B$13B5.8x5.4x18.4x17.1x
Salesforce$42B$13B5.5x5.2x17.8x12.2x
ServiceNow$13B$2.6B11.1x9.6x57.2x25.0x
Snowflake$4.7B($1.3B)25.6x21.0x(94.1x)121.7x
Adobe$24B$9.3B4.3x3.9x10.9x8.2x
Datadog$3.4B($588K)23.6x19.4x(137813.0x)77.6x

This data is available for Pro users. Sign up to see all NeoCura competitors and their valuation data.

Start Free Trial

Common questions about NeoCura

When was NeoCura founded?NeoCura was founded in 2017.
Where is NeoCura headquartered?NeoCura is headquartered in Beijing, China.
Is NeoCura publicly listed?No, NeoCura is a private, VC-backed company.
How much funding has NeoCura raised?NeoCura has raised $117M across 2 funding rounds.
What was NeoCura's last funding round?NeoCura's last funding round was a $79M Series A in December 2021, led by James Yahui and PICC Capital Investment Management.
Who are NeoCura's investors?NeoCura's investors include James Yahui, Kunlun Capital, IDG Capital, Alwin Capital, Jiayin Investment, Shunxi Fund, CDH Investments and PICC Capital Investment Management.
Which companies are comparable to NeoCura?Companies comparable to NeoCura include Tempus AI, SenseTime Group, Presight AI, XtalPi, Commure and Abridge.

See companies similar to NeoCura

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial